All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adjuvanted COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Government of Canada
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 22, 2020
Details:
Agreements relate to vaccine candidate using Sanofi’s recombinant protein-based technology and GSK’s pandemic adjuvant.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Virus-like-particle vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Serum Institute of India
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 08, 2020
Details:
SpyBiotech has signed an exclusive global licensing agreement with SIIPL for the development of a novel virus-like-particle (VLP) vaccine targeting COVID-19. The Phase I/II study has been initiated in Australia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMC-I109V
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-I109V
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
New preclinical data show potential of ImmTAV platform to facilitate specific and rapid elimination of Hepatitis B‐infected cells with the goal of achieving functional cure .
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Novavax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Partnership August 17, 2020
Details:
FUJIFILM's site in Billingham, UK will manufacture antigen component of NVX-CoV2373, Novavax' COVID-19 vaccine candidate. Billingham plans to begin production of the first batch at beginning of Q1, 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: BARDA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 03, 2020
Details:
FUJIFILM Diosynth Biotechnologies' College Station, Texas, site will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
Imperial College London in the UK has advanced its Covid-19 vaccine candidate into the next phase of the COVAC1 clinical trial following the success in the initial dose escalation phase involving 15 volunteers.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
Details:
Based on a new self-amplifying RNA (saRNA) technology, the vaccine was found to be safe and generated promising evidence of an effective immune response in pre-clinical safety tests and animal studies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $81.3 million Upfront Cash: Undisclosed
Deal Type: Funding May 17, 2020
Details:
The Government has announced £65.5 million of new funding for the vaccine being developed at the Oxford Vaccine Group as coronavirus vaccine trials accelerate. If the Oxford vaccine is successful, AstraZeneca will deliver 100 million doses in total worldwide.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Oxford University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 30, 2020
Details:
The collaboration aims at bringing to patients the potential vaccine known as ChAdOx1 nCoV-19, being developed by the Jenner Institute and Oxford Vaccine Group.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
